With nearly 30% shaved off the top of Idenix (IDIX -29%) today on the back of the FDA's partial...

|About: Idenix Pharmaceuticals, Inc. (IDIX)|By:, SA News Editor

With nearly 30% shaved off the top of Idenix (IDIX -29%) today on the back of the FDA's partial clinical hold placed on Phase 2 trials of its Hep c drug, Stifel Nicolaus steps in with a valuation upgrade. The firm raises the shares to Hold from Sell, noting that the hold is just temporary and likely to be resolved.